- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05134441
Studie för att utvärdera effektivitet, säkerhet och tolerabilitet av IMU-838 hos patienter med återfallande multipel skleros (ENSURE-1)
En multicenter, randomiserad, dubbelblind fas 3-studie för att utvärdera effektiviteten, säkerheten och toleransen av IMU-838 kontra placebo hos vuxna med återfallande multipel skleros (ENSURE-1)
Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This study will be a multicenter, randomized, double-blind, placebo-controlled study with a blinded Main Treatment Period (MT) and an Open Label Period (OLE) to evaluate the efficacy, safety, and tolerability of IMU-838 in adult patients with RMS. The study will consist of the following periods:
Screening Period: Approximately 28 days Main Treatment Period: Up to 72 weeks (approximately 15 months) Open Label Extension Period: Up to approximately 8 years
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
-
Tirana, Albanien, 1005
- Klinika Mjekesore Nuova, Neurology Clinic
-
Tirana, Albanien
- Hygeia Hospital Tirana
-
-
-
-
-
Algiers, Algeriet, 16000
- University Hospital Center Mustapha Pacha, Algiers
-
Annaba, Algeriet, 23000
- University Hospital Center Ibn Sina, Annaba
-
Oran, Algeriet, 31000
- University Hospital Center of Oran
-
-
-
-
-
Blagoevgrad, Bulgarien, 2700
- MHAT Puls AD
-
Burgas, Bulgarien, 8000
- MHAT "Heart and Brain", EAD
-
Pleven, Bulgarien, 5800
- MC Exacta Medica OOD
-
Pleven, Bulgarien, 5800
- MHAT Avis Medica
-
Pleven, Bulgarien, 5800
- UMHAT Dr.Georgi Stranski EAD
-
Pleven, Bulgarien
- Heart and Brain University Hospital
-
Pleven, Bulgarien
- MC Vita 1
-
Plovdiv, Bulgarien, 4002
- UMHAT Sveti Georgi
-
Plovdiv, Bulgarien, 4001
- UMHAT "Kaspela"EOOD
-
Plovdiv, Bulgarien, 4002
- UMHAT "Pulmed" Ltd
-
Rousse, Bulgarien
- UMHAT "Medica Ruse"
-
Sofia, Bulgarien, 1431
- UMHAT "Alexandrovska"
-
Sofia, Bulgarien, 1431
- UMHAT "Alexandrovska" EAD
-
Sofia, Bulgarien
- Military Medical Academy
-
Sofia, Bulgarien, 1606
- Military Medical Academy MHAT
-
Sofia, Bulgarien, 1000
- CCB Medical Institute Ministry of Interior
-
Sofia, Bulgarien, 1000
- Diagnostic and Consultative Center Neoclinic
-
Sofia, Bulgarien, 1000
- UMHAT "Sveti Ivan Rilski" EAD
-
Sofia, Bulgarien, 1113
- MHATNP "Sveti Naum", EAD
-
Sofia, Bulgarien, 1113
- MHATNPsy Sveti Naum EAD
-
Sofia, Bulgarien, 1618
- MHAT "Sveta Sofia" EOOD
-
Sofia, Bulgarien
- UMHAT"Tsaritsa Yoanna -ISUL
-
Sofia, Bulgarien
- UMHATEM N.Pirogov
-
Varna, Bulgarien
- UMHAT "Sveta Marina" EAD, First Clinic of Neurological Diseases
-
-
-
-
Arizona
-
Phoenix, Arizona, Förenta staterna, 85004
- Xenoscience, Inc., 21st Century Neurology
-
-
California
-
West Hollywood, California, Förenta staterna, 90048
- Regina Berkovich MD, PhD Inc. MS Neurology
-
-
Florida
-
Bradenton, Florida, Förenta staterna, 34205
- Bradenton Research Center
-
Naples, Florida, Förenta staterna, 34105
- Collier Neurologic Specialists
-
Ormond Beach, Florida, Förenta staterna, 32174
- Neurology Associates of Ormond Beach
-
-
Illinois
-
Northbrook, Illinois, Förenta staterna, 60062
- Consultants in Neurology, Ltd
-
-
-
-
-
Tbilisi, Georgien
- LTD Aversi Clinic
-
Tbilisi, Georgien, 0141
- 1st Uni Clinic of Tbilisi LEPL
-
Tbilisi, Georgien
- Eristavi Experimental Center
-
Tbilisi, Georgien
- J.S.C. Curatio Clinic
-
Tbilisi, Georgien
- Khechinashvili University Hospital
-
Tbilisi, Georgien
- LTD New Hospitals
-
Tbilisi, Georgien
- MediClub Georgia LLC
-
Tbilisi, Georgien
- Sarajishvili Neurology Institute
-
Tbilisi, Georgien
- JSC "Jerarsi"
-
Tbilisi, Georgien
- Pineo Medical Ecosystem LTD
-
-
-
-
-
Bangalore, Indien, 560092
- Medstar Speciality Hospital
-
Mangalore, Indien, 575002
- Mallikatte, Kadri
-
Nagpur, Indien
- Jasleen Hospital
-
New Delhi, Indien, 110060
- Sir Ganga Ram Hospital
-
Pune, Indien, 411001
- Ruby Hospital
-
Shimla, Indien, 171006
- Atal Institute of Medical Super Specialities (AIMSS)
-
Varanasi, Indien, 221005
- Institute of Medical Sciences Banaras Hindu University,IMS BHU Varanasi
-
-
-
-
-
Amman, Jordanien, 11942
- Jordan University Hospital
-
Amman, Jordanien, 11196
- Istiklal Hospital
-
Amman, Jordanien
- TSH Advanced Clinical Center
-
Irbid, Jordanien
- Irbid Speciality Hospital
-
-
-
-
-
Beirut, Libanon
- Hotel Dieu de France Hospital
-
Hamra, Libanon, 1107-2020
- AUB Medical Center
-
-
-
-
-
Kaunas, Litauen, 50161
- Lietuvos Sveikatos Mokslu Universitetas - Kauno Klinikos
-
-
-
-
-
Culiacán, Mexiko, 80020
- Neurociencias Estudios Clínicos S.C
-
Guadalajara, Mexiko, 44670
- Instituto Jalisciense de Metabolismo, SC
-
Mexico City, Mexiko, 14050
- Unidad de Investigación en Salud de Chihuahua S.C.
-
Mexico City, Mexiko
- Clinstile SA de CV
-
Mexico City, Mexiko, 03310
- Grupo medico camino SC
-
Mexico City, Mexiko, 06700
- Consultorio Médico Expert Brain Clinic
-
Morelia, Mexiko, 58000
- Centro de Morelia
-
Veracruz, Mexiko, 91900
- Sociedad de Metabolismo y Corazon, S.C.
-
Veracruz, Mexiko, 91900
- Faicic de RL de CV
-
-
-
-
-
Nikšić, Montenegro
- General Hospital Niksic
-
Podgorica, Montenegro
- Clinical Center of Montenegro
-
-
-
-
-
Chisinau, Mögel
- Instititute of Emergency Medicine
-
Chisinau, Mögel
- Medico-Sanitary Public Institution, Institute of Neurology and Neurosurgery "Diomid Gherman"
-
Chisinau, Mögel
- The Diomid Gherman Institute of Neurology and Neurosurgery
-
-
-
-
-
Skopje, Nordmakedonien
- Hospital "8 mi Septemvri"
-
Skopje, Nordmakedonien
- University Clinic of Neurology
-
-
-
-
-
Lublin, Polen, 20-064
- NZOZ Neuromed M. i M. Nastaj Sp. P.
-
-
-
-
-
Barnaul, Ryssland, 656045
- City Hospital #5, Barnaul
-
Barnaul, Ryssland, 656906
- Profimed LLC
-
Bryansk, Ryssland, 241033
- Bryansk Regional Hospital 1
-
Chelyabinsk, Ryssland, 454021
- Regional Clinical Hospital 3
-
Krasnoyarsk, Ryssland, 660037
- Federal Siberian Scientific and Clinical Centre of Federal Medical and Biological Agency
-
Kursk, Ryssland, 305007
- Kursk Regional Clinical Hospital
-
Nizhny Novgorod, Ryssland, 603076
- Medis LLC
-
Novosibirsk, Ryssland, 630004
- Sibneiromed LLC
-
Novosibirsk, Ryssland, 630007
- SDMCH SDMC of FMBA of Russia
-
Perm, Ryssland, 614045
- Perm State Medical University n.a. Acad. E. A. Vagner
-
Samara, Ryssland, 443095
- Samara regional clinical hospital n. a. V. L. Seredavin
-
Yekaterinburg, Ryssland, 620102
- Sverdlovsk Regional Clinical Hospital #1
-
-
-
-
-
Münster, Tyskland, 48149
- University Hospital Muenster, Institute Translational Neurology dept. Neurology
-
-
-
-
-
Chernihiv, Ukraina, 14029
- Communal Non-Commercial Enterprise "Chernihiv Regional Hospital",Department of Neurology
-
Chernivtsi, Ukraina, 58023
- Regional Municipal Non-commercial Enterprise "Chernivtsi Emergency Medical Hospital"
-
Chernivtsi, Ukraina
- Chernihiv Regional Hospital
-
Ivano-Frankivsk, Ukraina, 76008
- Regional Clinical Hospital
-
Ivano-Frankivsk, Ukraina, 76493
- Neuro Global, LLC
-
Khmelnytskyi, Ukraina
- Khmelnytsky regional hospital of war veterans
-
Kiev, Ukraina
- Clinical Hospital #15 of the Podilskyi District of the Kyiv City
-
Kyiv, Ukraina, 3037
- "Medbud"
-
Kyiv, Ukraina, 4212
- SMART medical center
-
Kyiv, Ukraina
- Kyiv City Hospital 4
-
Odesa, Ukraina
- Odesa Regional Clinical Hospital, Department of Neurosurgery
-
Poltava, Ukraina
- Medical and diagnostic center of a LLC "Medcontinent", neurology and rehabilitation center
-
Ternopil, Ukraina, 46027
- Ternopil Psycho-Neuro Hospital
-
Uzhhorod, Ukraina
- Regional Clinical Center for Neurosurgery and Neurology
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Male or female patient (age ≥18 to ≤55 years).
-
Patients with an established diagnosis of MS according to 2017 McDonald Criteria.
-
Patients with RMS comprising of relapsing remitting MS (RRMS) and active secondary progressive MS, both defined according to Lublin criteria 1996 and 2014.
-
Active disease as defined by Lublin 2014 evidenced prior to Screening by:
- At least 2 relapses in the last 24 months before randomization, or
- At least 1 relapse in the last 12 months before randomization, or
- A positive Gd+ MRI scan (brain and/or spine) in the last 12 months prior to randomization.
-
Willingness and ability to comply with the protocol.
-
Written informed consent given prior to any study-related procedure.
Exclusion Criteria:
- Patients with non-active secondary progressive MS and primary progressive MS.
- Any disease other than MS that may better explain the signs and symptoms, including history of complete transverse myelitis.
- Clinical signs or presence of laboratory findings suggestive for neuromyelitis optica (NMO) spectrum disorders or myelin oligodendrocyte glycoprotein (MOG)-IgG-associated encephalomyelitis
- Any active and uncontrolled coexisting autoimmune disease, other than MS (except for type 1 diabetes mellitus and inflammatory bowel disease)
- Use of experimental/investigational drug (with the exception ofCOVID-19 vaccines approved by emergency use authorization) and/or participation in drug clinical studies within 6 months prior to Screening
- Previous or current use of MS treatments lifelong, or within a pre-specified time period.
- Use of the pre-specified concomitant medications.
- Clinically significantly abnormal and pre-specified lab values.
- History of chronic systemic infections within 6 months before the date of informed consent.
- Diagnosis or suspected liver function impairment, which may cause fluctuating liver function tests during this study.
- Known history of nephrolithiasis or underlying condition with a strong association of nephrolithiasis.
- History or clinical diagnosis of gout.
- History or presence of any major medical or psychiatric illness
- Substantial medical condition that could create undue risk to the patient, could affect adherence with the study protocol or could undesirably affect study outcomes
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: IMU-838
IMU-838 (vidofludimus calcium), a small molecule inhibitor of DHODH. Formulation: Tablets with 15 or 30 mg IMU-838 for once daily oral intake in the morning. |
Patients are randomized to IMU-838 or placebo in ratio 1:1
Andra namn:
|
|
Placebo-jämförare: Placebo
Matching placebo, as described for the test product, identical number of tablets as given for IMU-838. |
Patients are randomized to IMU-838 or placebo in ratio 1:1
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
To evaluate efficacy of IMU-838 versus placebo regarding time to first relapse
Tidsram: 72 weeks
|
Survival analysis of time to first relapse, occurred after the start of study treatment administration and before the end of the double-blind period, censored at a maximum of 72 weeks. |
72 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Effect of IMU-838 versus placebo on volume of new T2 lesions
Tidsram: 72 weeks
|
To evaluate the effect of IMU-838 versus placebo on volume of new T2 lesions. Mean difference between IMU-838- and placebo in changes of the volume of new MRI T2 lesions over 24-weeks of treatment in the double-blind period. |
72 weeks
|
|
Effect of IMU-838 versus placebo on disability progression
Tidsram: 72 weeks
|
To evaluate the effect of IMU-838 versus placebo on disability progression. Survival analysis of time to 12-week confirmed disability progression, as measured on Expanded Disability Status Scale during the double-blind period, censored at maximum 72-weeks. |
72 weeks
|
|
Effect of IMU-838 versus placebo on cognitive performance
Tidsram: 72 weeks
|
To evaluate the effect of IMU-838 versus placebo on cognitive performance. Survival analysis of time to confirmed clinically relevant changes on Symbol Digit Modalities Test during the double-blind period, censored at maximum 72-weeks. |
72 weeks
|
|
Effect of IMU-838 versus placebo on whole brain atrophy
Tidsram: 72 weeks
|
To evaluate the effect of IMU-838 versus placebo on whole brain atrophy. Difference in the mean of the percentage change on the whole brain volume between IMU-838 and placebo during the 72-weeks double-blind period. |
72 weeks
|
|
Safety of IMU-838 versus placebo
Tidsram: 72 weeks
|
To evaluate safety and tolerability of IMU-838 versus placebo by assessing rates of Treatment Emergent Adverse Events, Adverse Events of Special Interest, Serious Adverse Events, changes in levels of pre-specified laboratory parameters, vital signs and ECG parameters and rates and reasons for study discontinuations. |
72 weeks
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Robert J. Fox, MD, Mellen Center for MS, Neurological Institute, Cleveland Clinic, Ohio
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- P3-IMU-838-RMS-01
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .